A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and Hypertension
← catalyst calendarSponsored by Mineralys Therapeutics Inc. (industry) · MLYS — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
48actual
Sites
27
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-02-28 | actual | When the study began enrolling |
| Primary completion | 2025-12-17 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-12-29 | actual | The whole study's end, after follow-up |
| First posted | 2025-01-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Obstructive Sleep Apnea
- Hypertension
Interventions
- Drug: Lorundrostat
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFPlacebo-adjusted Change From Baseline in AHI at Week 4
measured Baseline, Week 4
Permalink · MLYS's whole pipeline · Catalyst calendar · Every registered study · What changed